48.36
price down icon1.06%   -0.52
after-market Dopo l'orario di chiusura: 48.36
loading
Precedente Chiudi:
$48.88
Aprire:
$47.92
Volume 24 ore:
1.21M
Relative Volume:
1.41
Capitalizzazione di mercato:
$3.03B
Reddito:
$45.48M
Utile/perdita netta:
$169.95M
Rapporto P/E:
18.46
EPS:
2.62
Flusso di cassa netto:
$230.85M
1 W Prestazione:
-7.94%
1M Prestazione:
+28.65%
6M Prestazione:
+7.47%
1 anno Prestazione:
+67.16%
Intervallo 1D:
Value
$47.09
$48.80
Intervallo di 1 settimana:
Value
$47.09
$53.58
Portata 52W:
Value
$24.22
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
Nome
Protagonist Therapeutics Inc
Name
Telefono
(510) 474-0170
Name
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
PTGX's Discussions on Twitter

Confronta PTGX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
48.36 3.03B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-06 Iniziato BMO Capital Markets Outperform
2024-12-06 Iniziato Goldman Neutral
2024-11-05 Iniziato Wedbush Outperform
2024-09-24 Iniziato TD Cowen Buy
2024-09-09 Iniziato Truist Buy
2023-10-30 Iniziato CapitalOne Overweight
2023-05-25 Ripresa Jefferies Buy
2022-08-25 Iniziato JMP Securities Mkt Outperform
2022-02-11 Iniziato BTIG Research Buy
2021-10-12 Aggiornamento JP Morgan Neutral → Overweight
2021-10-11 Aggiornamento Northland Capital Market Perform → Outperform
2021-09-20 Downgrade JP Morgan Overweight → Neutral
2021-05-24 Iniziato JMP Securities Mkt Outperform
2021-05-24 Iniziato Northland Capital Outperform
2021-01-06 Iniziato JP Morgan Overweight
2020-12-16 Iniziato Piper Sandler Overweight
2020-09-18 Reiterato H.C. Wainwright Buy
2020-07-15 Iniziato Jefferies Buy
2020-05-18 Reiterato H.C. Wainwright Buy
2019-07-08 Iniziato H.C. Wainwright Buy
2019-05-09 Aggiornamento Stifel Hold → Buy
2018-12-06 Iniziato Nomura Buy
2018-01-29 Iniziato Stifel Buy
2017-07-21 Iniziato BTIG Research Buy
Mostra tutto

Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie

pulisher
Mar 25, 2025

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance

Mar 25, 2025
pulisher
Mar 23, 2025

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph

Mar 23, 2025
pulisher
Mar 22, 2025

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire

Mar 20, 2025
pulisher
Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 18, 2025

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

Mar 18, 2025
pulisher
Mar 18, 2025

Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan

Mar 18, 2025
pulisher
Mar 15, 2025

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 15, 2025
pulisher
Mar 15, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa

Mar 15, 2025
pulisher
Mar 15, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada

Mar 15, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Learn to Evaluate (PTGX) using the Charts - Stock Traders Daily

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics price target raised to $76 from $60 at Truist - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance UK

Mar 11, 2025
pulisher
Mar 11, 2025

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - Simply Wall St

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Gets IBD Stock Rating Upgrade - Investor's Business Daily

Mar 11, 2025
pulisher
Mar 11, 2025

10 Firms Buck Market Bloodbath on Monday - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics’ (PTGX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

PTGX stock soars to 52-week high, reaching $50.18 By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

BTIG maintains Buy on Protagonist Therapeutics, target at $73 By Investing.com - Investing.com Canada

Mar 10, 2025

Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):